TOP
STORY

To map nonhematopoietic cells and structures in bone and bone marrow, investigators performed multicolor 3D imaging of osteoblastic, vascular, perivascular, neuronal and marrow stromal cells, and extracellular-matrix proteins in whole mouse femurs. They analyzed potential interactions between cells and molecules on the basis of colocalization of markers. [Nat Biotechnol]
Abstract

Researchers showed that endothelial NOTCH1 is responsive to shear stress, and is necessary for the maintenance of junctional integrity, cell elongation, and suppression of proliferation, phenotypes induced by laminar shear stress. NOTCH1 receptor localized downstream of flow and canonical NOTCH signaling scaled with the magnitude of fluid shear stress. [Nat Commun]
Full Article

The authors investigated the effect of hematopoietic-substrate-1 associated protein X-1 (HAX-1) on the proliferation and apoptosis endothelial precursor cells (EPCs) and explored its mechanism. According to their results, HAX-1 was overexpressed in EPCs. The results of clone formation and Edu proliferation assay showed that HAX-1 promoted EPCs’ multiplication. [Stem Cells]
Abstract

The authors provide a broad, balanced perspective on the current understanding of drug transport to tumor cells and on the progress in developing methods to enhance drug delivery. [Nat Rev Cancer]
Abstract

Brahim Chaqour, PhD, professor of cell biology and ophthalmology at SUNY Downstate Medical Center, has received two awards to support research into treatment of currently incurable vision-threatening diseases. The new awards, totaling $2,008,973, are from the National Eye Institute of the National Institutes of Health. [SUNY Downstate Medical Center]
Press Release

The government said that it would boost public spending on research and development to £12.5 billion in 2021–22, an increase of £500 million on what is already planned for the year before. The rise builds on a surprise announcement made last year, when politicians promised yearly increases in research funding until 2020. [Nature News]
Editorial

The FDA announced a comprehensive policy framework for the development and oversight of regenerative medicine products, including novel cellular therapies. The framework – outlined in a suite of four guidance documents – builds upon the FDA’s existing risk-based regulatory approach to more clearly describe what products are regulated as drugs, devices, and/or biological products. [U.S. Food and Drug Administration]
Press Release